Jazz Pharmaceuticals plc JAZZ · NASDAQ
$208.43 -0.86% (-$1.80)
Summary
75 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 20 USD is left as net profit.
- It earns 19 USD a year on every 100 USD of invested capital.
- The share price is below the Bulios Fair Price.
- Analysts expect revenue to grow by 11% this fiscal year.
What to watch
- Revenue growth is slowing: 5.3% a year over the last 3 years against 13% over 5 years.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 14.4 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 5.3% a year. For the next fiscal year analysts expect revenue to grow by 11%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 15 USD
- Research and development 16 USD
- Sales and administration 37 USD
- Taxes and other 11 USD
- Net profit 20 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 20 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.9 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 43
- Hold 5
- Sell 0
Today's price within the analysts' price targets
The average target of $292.67 is 40% above today's price. 90% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Xywav 40%
- Epidiolex/Epidyolex 25%
- Rylaze/Enrylaze 9.6%
- Zepzelca 7.3%
- High Sodium AG Oxybate Product Royalty Revenue 5.1%
- Other 13%
By region
- UNITED STATES 90%
- Europe 8.0%
- Other Countries 2.2%
Xywav brings in 40% of revenue.
Segments in detail